When Pharmaceutical Pricing Meets Evidence-based Medicine

Insurance and pharmaceutical companies are increasingly signing contracts linking a products performance to its price. Though this is not a solution to the pharmaceutical pricing problems we currently face, it is a step in the right direction. Read more here. (Source: David brooks, Granite geek,4/6/17)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
Accelerated Expansion of MEDiSTRAVA With Acquisition of… 05/21/2019